Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden‘s administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this category? Which stocks are thriving in these sectors?
Schedule III substances, according to the DEA, have accepted medical value and low addiction possibility. Examples of Schedule III drugs include testosterone, codeine, ketamine, anabolic steroids and certain medications.
Stocks To Watch In Schedule III
Ketamine Investments
Johnson & Johnson (NYSE: JNJ), with an enterprise value (EV) of $378.09 billion and a market cap of $372.24 billion, stands as a dominant force in the ketamine market with significant investments in innovative treatments like Spravato.
MindMed (NASDAQ: MNMD), an early-stage company with a market cap of $583.75 million and an EV of $348.43 million, is pioneering psychedelic research, particularly in ketamine derivatives. Despite its current unprofitability, analysts rate MindMed as a strong buy due to its promising pipeline and innovative treatment approaches.
Cybin Inc. (NYSEAMERICAN: CYBN), with a market cap of $262.63 …